医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vitruvias Therapeutics and Sunny Pharmtech Receive First FDA Generic Drug Approval

2017年09月27日 PM08:00
このエントリーをはてなブックマークに追加


 

AUBURN, Al. & TAIPEI, Taiwan

Sunny Pharmtech Inc., a Taiwan-based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced they have received approval of their abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Lidocaine Ointment USP 5%.

This is the first generic approval for both companies and is part of a joint development agreement that now includes eight products. The joint application was filed in November of 2016, and received first-cycle approval after a 10 month review.

“We are pleased to have received such a timely approval with our first jointly filed application,” said Dr. Yon-Lian Wu, Sunny Pharmtech’s CEO and Chairperson. “It is a testament to competence and capabilities of both companies’ development and regulatory groups that our first application was approved so quickly”.

Carl Whatley, General Manager of Vitruvias added, “It is very exciting to receive our first joint approval, and we are looking forward to beginning the commercial phase of our business plan. This approval represents our transition from a purely developmental company to one that can discover, develop and commercialize technically complex generics.”

About Sunny Pharmtech Inc.

Sunny Pharmtech Inc. is an emerging specialty pharmaceutical company based in Taiwan and was founded in 2004 with a focus on the development of technically difficult products. In 2014, the capability of developing and producing active pharmaceutical ingredients was added. The resulting organization is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products which includes orals, liquids, semi-solids, and parenterals. www.sunnypharmtech.com/home/

About Vitruvias Therapeutics LLC

Vitruvias is an emerging specialty pharmaceutical company which develops, manufactures, and markets generic prescription products for the U.S. and Canadian markets. Founded in 2013, the privately-held company specializes in generic semi-solid and parenteral products. The current focus of the company is on the development of selective, high-value generic products. www.vitruvias.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170927005129/en/

CONTACT

Vitruvias Therapeutics LLC
Carl Whatley, 334-329-5601
Email: carl@vitruvias.com
or
Sunny
Pharmtech Inc.
Newman Pui, +886 22664-9600
newman.pui@sunnypharmtech.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作